About this Research Topic
Solid organ transplant (SOT) recipients have an increased risk of various types of cancer due to chronic immunosuppression, and this is the leading cause of mortality in SOT recipients. The incidence of cancer in SOT recipients is increasing as a result of increased number of transplants performed and the improved long-term survival of SOT. Immunotherapy, such as immune checkpoint inhibitors and cellular therapies, have revolutionized the landscape of cancer treatment, with an expanding spectrum of indications. However, its application in the subset of patients with SOT is still no well-established, due to the limited data regarding its safety and efficacy in SOT recipients. In addition, further studies are needed to develop optimal immunosuppression management, to identify potential predictive and prognostic biomarkers, and to guide multidisciplinary care.
The goal of this Research Topic is to provide a forum to advance research on the latest developments in cancer immunotherapy for SOT recipients. This includes the clinical application of immunotherapy in SOT recipients with various cancer types, and at different disease stages and treatment settings; the management of immunosuppression for cancer patients with SOT; elucidation of immune-biologic mechanisms and identification of biomarkers to guide the patient selections and optimal therapy, as well as the multidisciplinary approach to improve the outcomes for these complex patient population. By bringing together leading experts in this multidisciplinary field, this Special Topic aims to provide an overview of the current state of cancer immunotherapy in SOT recipients, and to promote further research development in this critical topic in the era of modern immunotherapy.
We welcome submissions of Original Research, Case Series, and Mini Review, Review and Perspective Articles. Themes for this Research Topic include, but not limited to:
(1) The application of cancer immunotherapy (such as immune checkpoint inhibitors, and cellular therapy) in patients with SOT.
(2) Development in neoadjuvant and adjuvant immunotherapy for cancer patients who are SOT recipients.
(3) Management of immunosuppression in cancer patients who had SOT.
(4) Evaluation and management of toxicities (such as transplant rejection) in SOT recipient treated with cancer immunotherapy.
(5) Immune-biological mechanism and translational research to identify potential biomarkers and therapeutic targets to guide immunotherapy for cancer patients who had SOT.
(6) Multidisciplinary management for cancer patients who had SOT in the era of modern immunotherapy (e.g., team approach for early cancer detection, surgical management).
Please note, manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
The goal of this Research Topic is to provide a forum to advance research on the latest developments in cancer immunotherapy for SOT recipients. This includes the clinical application of immunotherapy in SOT recipients with various cancer types, and at different disease stages and treatment settings; the management of immunosuppression for cancer patients with SOT; elucidation of immune-biologic mechanisms and identification of biomarkers to guide the patient selections and optimal therapy, as well as the multidisciplinary approach to improve the outcomes for these complex patient population. By bringing together leading experts in this multidisciplinary field, this Special Topic aims to provide an overview of the current state of cancer immunotherapy in SOT recipients, and to promote further research development in this critical topic in the era of modern immunotherapy.
We welcome submissions of Original Research, Case Series, and Mini Review, Review and Perspective Articles. Themes for this Research Topic include, but not limited to:
(1) The application of cancer immunotherapy (such as immune checkpoint inhibitors, and cellular therapy) in patients with SOT.
(2) Development in neoadjuvant and adjuvant immunotherapy for cancer patients who are SOT recipients.
(3) Management of immunosuppression in cancer patients who had SOT.
(4) Evaluation and management of toxicities (such as transplant rejection) in SOT recipient treated with cancer immunotherapy.
(5) Immune-biological mechanism and translational research to identify potential biomarkers and therapeutic targets to guide immunotherapy for cancer patients who had SOT.
(6) Multidisciplinary management for cancer patients who had SOT in the era of modern immunotherapy (e.g., team approach for early cancer detection, surgical management).
Please note, manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Keywords: immunotherapy, solid tumors, transplants, cancer treatment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
